Apple Tree Partners related stories
All articles and analysis
Farrell joins Pillar VC as CFOPreviously, she was CFO for Apple Tree Partners.
- Nereid Therapeutics pulls in $50m Series A
Cambridge, Massachusetts-based Nereid Therapeutics, a newly launched drug developer, has raised $50 million in Series A funding.
- Chinook Therapeutics bags $106m in latest financing
Chinook Therapeutics, a Vancouver, British Columbia-based developer of precision medicines for kidney disease, has raised US$106 million in financing.
Nine Square Therapeutics nets $50m Series ASan Francisco-based Nine Square Therapeutics, a developer of new treatments for movement disorders, has raised $50 million in Series A funding.
- VC-backed Chinook Therapeutics to merge with Aduro Biotech
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has agreed to merge with Aduro Biotech.
Limelight Bio snags $75 mlnPhiladelphia and Cambridge, Massachusetts-based Limelight Bio, a biopharmaceutical company developing novel gene therapies, has raised $75 million in financing.
Chinook Therapeutics snags Series AChinook Therapeutics has raised US$65 million in Series A financing. Versant Ventures led the round with participation from Apple Tree Partners and Samsara BioCapital. Based in Seattle and Vancouver, British Columbia, Chinook is a developer of precision medicines for kidney diseases.
- Chinook Therapeutics secures $86 mln in Series A financing
Chinook Therapeutics, a Vancouver-based developer of precision medicines for kidney disease, has raised about $86 million (US$65 million) in a Series A financing. U.S. life sciences venture capital firm Versant Ventures led the round, with participation from Apple Tree Partners and Samsara BioCapital. Chinook was incubated through Versant's Inception Sciences and seeded by Versant and Apple Tree. Chinook's technology leverages single-cell RNA sequencing, human-derived organoids and new translational models to develop therapeutics with novel mechanisms of action against kidney disease pathways. Led by President and CEO Eric Dobmeier, the company will use the funds raised to advance several programs into clinical trials by 2021.
- VC-backed Akero Therapeutics debuts IPO
Akero Therapeutics Inc, a biotech firm, has raised about $92 million for its IPO after pricing its 5.75 million shares at $16 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol "AKRO." J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are the lead underwriters. Akero's pre-IPO investors included Janus Henderson Investors, Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, LifeSci Venture Partners, Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.
